Lesser Curvature and Omentum-Dependent Spindle Cell Tumor: Literature Review Regarding a Case
Main Article Content
Abstract
GIST tumors are a group of rare neoplasms, having a reported incidence of 6/10 million people annually. 70-80% of the GIST are benign, however there are prognostic factors which can help us to predict its behavior. The stomach and the small intestine are the most frequent sites of location of these tumors. Diagnosis is not only based on clinical suspicion, we must also use imaging tools and pathology to confirm it. Surgery is the treatment that offers a permanent cure for localized primary GIST.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Mazur, M, Clark, H. Gastric stromal tumors. Reappraial of histogenesis. The American journal of surgical pathology 1983; 7: 507-19.
II. DeMatteo, R, Lewis, J, Leung, D, et al. Two hundred gastrointestinal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51–58.
III. Licht, J, Weissmann, L, Antman, K. Gastrointestinal sarcomas. Semin Oncol 1988; 15: 181–188.
IV. Walker, P, Dvorak, A. Gastrointestinal autonomic nerve (GAN) tumor: ultra-structural evidence for a newly recognized entity. Arch Pathol Lab Med 1986; 110: 309–316.
V. Appleman, HD. Mesenchymal tumors of the gut: histological perspectives, new approaches, new results, and does it make any difference. Monogr Pathol 1990; 31: 220–246.
VI. Kindblom, L, Remotti, H, Aldenborg, F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259–1269.
VII. Miettinen, M, Virolainen, M, Maarit, S. Gastrointestinal stromal tumors—value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 1995; 19: 207–216.
VIII. Miettinen, M, Monihan, J, Sarlomo- Rikala, M, et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary to the omentum and mesentery. Am J Surg Pathol 1999; 23: 1109–1118.
IX. Tran, T, Davila, J, El-Serag, H. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. American Journal of Gastroenterology 2005; 100: 162-168.
X. Inoue, A, Ota, S, Yamasaki, M, et al. Gastrointestinal stromal tumors: A comprehensive radiological review. Jpn. J. Radiol 2022; 40: 1105–1120.
XI. Vernuccio, F, Taibbi, A, Picone, D, et al. Imaging of Gastrointestinal Stromal Tumors: From Diagnosis to Evaluation of Therapeutic Response. Anticancer Res 2016; 36: 2639–2648.
XII. Poveda, A, Martinez, V, Serrano, C, et al. SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016). Clin. Transl.Oncol 2016; 18: 1221–1228.
XIII. Sugiyama, Y, Sasaki, M, Kouyama, M, et al. Current treatment strategies and future perspectives for gastrointestinal stromal tumors. World J. Gastrointest. Pathophysiol 2022; 13: 15–33.
XIV. Stanciulea, O, Ionescu, M, Blanita, D, et al. Minimal Access Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumours-A Single Centre Experience. Chirurgia 2020; 115: 726–734.
XV. Taylor, M, Katherine, F, Paul, T. Population-Based Epidemiology and Mortality of Small Malignant Gastrointestinal Stromal Tumors in the USA. J Gastrointest Surg 2016; 20(6): 1132–1140.
XVI. Miettinen, M, Sarlomo-Rikala, J, Lasota J. Gastrointestinal stromal tumors – new findings on their biology. A review. Hum Pathol 1999; 23: 1209–1220.
XVII. Miettinen, M, Sarlomo-Rikala, M, Sobin, L, et al. Colonic stromal tumors and leiomyosarcomas. A clinicopathologic, immunohistochemical and molecular genetic study of 44 cases. Am J Surg Pathol 2000; 24(10): 1339-1352.
XVIII. Alcantara, A, Chapa, O, Díaz, L. Gastrointestinal stromal tumor: pathological and clinical characteristics in the population of the General Hospital of Mexico “Dr. Eduardo Liceaga”. Artículo Original, Rev Med Hosp Gen Mex 2019; 82(1): 4-10.
XIX. Costache, M, Filip, B, Scripcariu, D, et al. Management of Gastric Stromal Tumour-Multicenter Observational Study. Chirurgia 2018. 113: 780–788.
XX. Skandalakis, J, Gray, S. Smooth muscle tumors of the alimentary tract. In: Ariel IM, ed. Progress in Clinical Cancer. New York: Grune & Stratton; 1965: 692–708.
XXI. Medina, F, Aguilar, J, Medina, Z. Tumores del estroma gastrointestinal. Analisis de factores pronósticos en un grupo de pacientes mexicanos. Gac Med Mex 2009; 146: 91-96.
XXII. Rammohan, A, Sathyanesan, J, Rajendran, K, et al. A gist of gastrointestinal stromal tumors: A review. World J. Gastrointest. Oncol 2013; 5: 102–112.
XXIII. Inoue, A, Ota, S, Yamasaki, M, et al. Gastrointestinal stromal tumors: A comprehensive radiological review. Jpn. J. Radiol 2022; 40: 1105–1120.
XXIV. Sripathi, S, Rajagopal, K, Srivastava, R, et al. CT features, mimics and atypical presentations of gastrointestinal stromal tumor (GIST). Indian J. Radiol. Imaging 2011; 21: 176–181.
XXV. Miettinen, M, Lasota, J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70-83.
XXVI. DeMatteo, R, Gold, J, Saran, L, et al. Tumor mitotic rate, size and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008; 112: 605-615.
XXVII. Jumniensuk, C, Charoenpitakchai, M. Gastrointestinal stromal tumor: Clinicopathological characteristics and pathologic prognostic analysis. World J. Surg. Oncol 2018; 16: 231.
XXVIII. Koelz, M, Lense, J, Wrba, F, et al. Down-regulation of miR-221 and miR-222 correlates with pronounced kit expression in gastrointestinal stromal tumors. Int J Oncol 2011; 38: 503-511.
XXIX. Stanciulea, O, Ionescu, M, Blanita, D, et al. Minimal Access Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors-A Single Centre Experience. Chirurgia 2020; 115: 726–734.
XXX. Moga, D, Vla ̆doiu, G, Fra ̆t,ila ̆, A, et al. Understanding Gastric GIST: From Pathophysiology to Personalized Treatment. J. Clin. Med 2024; 13: 3997.
XXXI. Casali, P, Blay, J, Abecassis, N, et al. Gastrointestinal stromal tumors: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol 2022; 33: 20–33.